HEPHESTOS - Hereditary Pheochromocytoma Assessment of Tumour Immunologies

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

⁃ Part I:

• Newly diagnosed patients with PPGL or newly diagnosed patients with (metastatic) PPGL recurrence.

• OR patients with mutations which predispose for the development of PPGL.

• Aged \> 18 years.

⁃ Part II:

• Confirmed PPGL on pathology.

• Aged \> 18 years.

Locations
Other Locations
Netherlands
Radboudumc
RECRUITING
Nijmegen
Contact Information
Primary
Kai Xu, M.D.
kai.xu@radboudumc.nl
+316 42385270
Backup
Marieke de Laat, M.D. PhD
marieke.delaat@radboudumc.nl
+3124 361 4599
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2029-06-01
Participants
Target number of participants: 200
Treatments
Patients with hereditary PPGL
Blood will be collected prior and after surgery for their pheochromocytoma/paraganglioma (as planned by their treating physician). Blood will also be collected prospectively during regular follow-up appointments after 1 year and after 2 years.
Patients with sporadic PPGL
Blood will be collected prior and after surgery for their pheochromocytoma/paraganglioma (as planned by their treating physician). Blood will also be collected prospectively during regular follow-up appointments after 1 year and after 2 years.
Asymptomatic carriers of germline mutations predisposing for PPGL
Blood will be collected at inclusion, after 1 year and after 2 years.
Sex and age matched healthy volunteers
Blood material will be obtained from healthy anonymous donors according to the protocol Donation of blood by healthy volunteers for experimental in-vitro research (Human Subjects Review Board approval number: NL84281.091.23).
Related Therapeutic Areas
Sponsors
Leads: Radboud University Medical Center

This content was sourced from clinicaltrials.gov